Literature DB >> 32115683

Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.

R Asero1, A V Marzano2,3, S Ferrucci2, M Lorini4, V Carbonelli4, M Cugno3,5.   

Abstract

Chronic spontaneous urticaria (CSU) pathogenesis shows a complex and still unclear interplay between immunoglobulin (Ig)G- and IgE-mediated autoimmunity, leading to mast cell and basophil degranulation and wheal formation. The objective of this study was to evaluate at the same time IgE- and IgG-reactivity to well recognized and recently reported autoantigens in CSU patients, and to assess the effects of such reactivity on response to the anti-IgE monoclonal antibody omalizumab. Twenty CSU patients underwent omalizumab treatment. Urticaria activity score 7 (UAS7) was recorded at baseline and at different drug administration time-points for categorizing early-, late- or non-responders. At baseline, sera from the 20 patients and from 20 controls were tested for IgE and IgG autoantibodies to high- and low-affinity IgE receptors (FcεRI and FcεRII), tissue factor (TF) and thyroglobulin (TG) by immunoenzymatic methods. Antibody levels were compared with those of controls and analysed according to response. Eighteen patients were omalizumab responders (11 early and seven late), while two were non-responders. More than 50% of patients had contemporary IgE and IgG to at least to one of the four different autoantigens. Late responders showed higher levels of both anti-TF IgE and IgG than early responders (P = 0·011 and P = 0·035, respectively). Twenty-five per cent of patients had levels of anti-FcεRI IgE, exceeding the upper normal limit, suggesting that it could be a novel auto-allergen in CSU. In CSU, there is an autoimmune milieu characterized by the co-existence of IgE and IgG autoantibodies to the same antigen/allergen, particularly in late responders to omalizumab, possibly explaining the slower response.
© 2020 British Society for Immunology.

Entities:  

Keywords:  IgE; IgG; autoimmunity; omalizumab; urticaria

Mesh:

Substances:

Year:  2020        PMID: 32115683      PMCID: PMC7231996          DOI: 10.1111/cei.13428

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria.

Authors:  C E Grattan; D M Francis; M Hide; M W Greaves
Journal:  Clin Exp Allergy       Date:  1991-11       Impact factor: 5.018

2.  Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.

Authors:  Janine Gericke; Martin Metz; Tatevik Ohanyan; Karsten Weller; Sabine Altrichter; Per Stahl Skov; Sidsel Falkencrone; Janko Brand; Arno Kromminga; Tomasz Hawro; Martin K Church; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2016-11-09       Impact factor: 10.793

3.  Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes.

Authors:  B L Gruber; M L Baeza; M J Marchese; V Agnello; A P Kaplan
Journal:  J Invest Dermatol       Date:  1988-02       Impact factor: 8.551

4.  Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients.

Authors:  A Leznoff; G L Sussman
Journal:  J Allergy Clin Immunol       Date:  1989-07       Impact factor: 10.793

5.  IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria.

Authors:  Oliver Schmetzer; Elisa Lakin; Fatih A Topal; Patricia Preusse; Denise Freier; Martin K Church; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2017-12-05       Impact factor: 10.793

6.  Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.

Authors:  Gustavo Deza; Marta Bertolín-Colilla; Silvia Sánchez; Dulce Soto; Ramon M Pujol; Ramon Gimeno; Ana M Giménez-Arnau
Journal:  J Allergy Clin Immunol       Date:  2018-03-05       Impact factor: 10.793

7.  Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?

Authors:  E Fiebiger; D Maurer; H Holub; B Reininger; G Hartmann; M Woisetschläger; J P Kinet; G Stingl
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

8.  Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.

Authors:  Gustavo Deza; Marta Bertolín-Colilla; Ramon M Pujol; Laia Curto-Barredo; Dulce Soto; Maribel García; Pilar Hernández; Ramon Gimeno; Ana M Giménez-Arnau
Journal:  Acta Derm Venereol       Date:  2017-06-09       Impact factor: 4.437

9.  Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.

Authors:  Laura Maggi; Beatrice Rossettini; Gianni Montaini; Andrea Matucci; Alessandra Vultaggio; Alessio Mazzoni; Boaz Palterer; Paola Parronchi; Enrico Maggi; Francesco Liotta; Francesco Annunziato; Lorenzo Cosmi
Journal:  Eur J Immunol       Date:  2018-10-09       Impact factor: 5.532

10.  IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?

Authors:  Sabine Altrichter; Hans-Jürgen Peter; Dina Pisarevskaja; Martin Metz; Peter Martus; Marcus Maurer
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

View more
  9 in total

Review 1.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

Review 2.  The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria.

Authors:  Bingjing Zhou; Jie Li; Runqiu Liu; Lei Zhu; Cong Peng
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

Review 3.  Role of Basophils in a Broad Spectrum of Disorders.

Authors:  Kensuke Miyake; Junya Ito; Hajime Karasuyama
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 4.  Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review.

Authors:  Melanie Mitsui Wong; Paul Kevin Keith
Journal:  Allergy Asthma Clin Immunol       Date:  2020-08-04       Impact factor: 3.406

Review 5.  Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.

Authors:  Jasmine Chang; Leila Cattelan; Moshe Ben-Shoshan; Michelle Le; Elena Netchiporouk
Journal:  J Asthma Allergy       Date:  2021-03-09

6.  Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.

Authors:  Martin Metz; Gordon Sussman; Rémi Gagnon; Petra Staubach; Tonny Tanus; William H Yang; Jeremy J Lim; Holly J Clarke; Joshua Galanter; Leslie W Chinn; Tom Chu; Anastasia Teterina; Tracy Burgess; D James Haddon; Timothy T Lu; Marcus Maurer
Journal:  Nat Med       Date:  2021-11-08       Impact factor: 53.440

7.  Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Authors:  Emek Kocatürk; Emel Bülbül Başkan; Özlem Su Küçük; Mustafa Özdemir; Sinem Örnek; Pelin Kuteyla Can; Eda Haşal; Burhan Engin; Nilgün Atakan; Erkan Alpsoy
Journal:  An Bras Dermatol       Date:  2022-07-16       Impact factor: 2.113

8.  Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma.

Authors:  Veronika Naumova; Evgeny Beltyukov; Katarzyna Niespodziana; Peter Errhalt; Rudolf Valenta; Alexander Karaulov; Darina Kiseleva
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

9.  Systemic and local evidence for complement involvement in chronic spontaneous urticaria.

Authors:  Mehran Alizadeh Aghdam; Mignon van den Elzen; Harmieke van Os-Medendorp; Marijke R van Dijk; Edward F Knol; André C Knulst; Heike Röckmann; Henny G Otten
Journal:  Clin Transl Allergy       Date:  2021-07-03       Impact factor: 5.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.